Table 2:
Demographics and medication use characteristics of patients with cystic fibrosis who received CFTR modulators between 2012-2018
| PS-CF (n=279) |
PI-CF (n=1516) |
p-value | |
|---|---|---|---|
| Age (in years) (mean (SD)) | 25.7 (15.5) | 19.8 (12.2) | <0.0001 |
| Age Group (in years) | <0.0001 | ||
| 0-5 | 30 (10.8%) | 169 (11.2%) | |
| 6-11 | 22 (7.9%) | 236 (15.6%) | |
| 12-17 | 39 (14.0%) | 322 (21.2%) | |
| 18-25 | 61 (21.9%) | 379 (25.0%) | |
| 26-34 | 56 (20.1%) | 221 (14.6%) | |
| 35+ | 71 (25.5%) | 189 (12.5%) | |
| Sex | 0.0004 | ||
| Male | 120 (43.0%) | 828 (54.6%) | |
| Female | 159 (57.0%) | 688 (45.4%) | |
| Plan Type | 0.0258 | ||
| Comprehensive | 10 (3.6%) | 20 (1.3%) | |
| EPO | 2 (0.7%) | 12 (0.8%) | |
| HMO | 35 (12.5%) | 170 (11.2%) | |
| POS | 19 (6.8%) | 140 (9.2%) | |
| PPO | 158 (56.6%) | 897 (59.2%) | |
| POS with capitation | 1 (0.4%) | 7 (0.5%) | |
| CDHP | 34 (12.2%) | 119 (7.9%) | |
| HDHP | 16 (5.7%) | 118 (7.8%) | |
| Unknown | 4 (1.4%) | 33 (2.2%) | |
| Region | 0.1185 | ||
| Northeast | 65 (23.3%) | 277 (18.3%) | |
| North Central | 79 (28.3%) | 401 (29.5%) | |
| South | 97 (34.8%) | 599 (39.5%) | |
| West | 35 (12.5%) | 229 (15.1%) | |
| Unknown | 3 (1.1%) | 10 (0.7%) | |
| Charlson Comorbidity Index (mean (SD)) | 0.6 (1.0) | 0.3 (0.7) | <0.0001 |
| Alcohol Abuse | 0 (0.0%) | 4 (0.3%) | 1.0000 |
| Any CFTR modulator use | 279 (100.0%) | 1516 (100.0%) | N/A |
| CFTR Modulator | <0.0001 | ||
| Ivacaftor ONLY | 170 (60.9%) | 356 (23.5%) | |
| Lumacaftor/ivacaftor ONLY | 49 (17.6%) | 765 (50.5%) | |
| Tezacaftor/ivacaftor ONLY | 48 (17.2%) | 269 (17.7%) | |
| Ivacaftor AND tezacaftor/ivacaftor | 4 (1.4%) | 7 (0.5%) | |
| Lumacaftor/ivacaftor AND tezacaftor/ivacaftor | 8 (2.9%) | 119 (7.9%) | |
| Percentage of time on CFTR modulator (mean (SD)) | 42 (31) | 53 (34) | <0.0001 |
| Time on CFTR modulators (years) | 0.6841 | ||
| Mean (SD) | 1.4 (1.2) | 1.4 (1.2) | |
| Median (IQR) | 1.2 (0.5-1.9) | 1.0 (0.5-2.0) | |
| Range | 0.0-6.9 | 0.0-6.9 | |
| Aggregate time on CFTR modulators (patient-years) | 402 | 2138 | N/A |
| Aggregate time without CFTR modulator use (patient years) | 699 | 3009 | N/A |
| Follow up available (years) | 0.0001 | ||
| Mean (SD) | 3.9 (2.1) | 3.4 (2.2) | |
| Median (IQR) | 3.9 (2.0-5.9) | 2.9 (1.2-5.5) | |
| Range | 0.3-7.0 | 0.3-7.0 | |
| Experienced ≥1 admission for AP1 | 8 (2.9%) | 14 (0.9%) | 0.007 |
| Total acute pancreatitis admissions1 | 13 | 18 | N/A |
1
Based on primary diagnoses (some have multiple admissions)
Consumer-driven health plan (CDHP); Cystic fibrosis transmembrane conductance regulator (CFTR); Exclusive provider organization (EPO); High-deductible health plan (HDHP); Health maintenance organization (HMO); Interquartile range (IQR); Pancreas-Insufficient CF (PI-CF); Point-of-service (POS); Pancreas-sufficient CF (PS-CF); Preferred provider organization (PPO); Standard deviation (SD)